• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

    26.00 +0.88 (+3.48%)
    Streaming Delayed Price Updated: 11:58 AM EST, Jan 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 556,161
    Open 25.09
    Bid (Size) 25.98 (200)
    Ask (Size) 26.00 (200)
    Prev. Close 25.12
    Today's Range 25.00 - 26.12
    52wk Range 16.10 - 35.57
    Shares Outstanding 116,457,008
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Apellis Pharmaceuticals Inc (NASDAQ:APLS) Fits the 'Growth at a Reasonable Price' Strategy ↗
    Apellis Pharmaceuticals exemplifies the GARP strategy with strong revenue growth, fair biotech valuation, and solid profitability margins. 
    Via Chartmill
    News headline image
    Arteris Fortifies AI-Driven Future with Strategic Acquisition of Cycuity, Championing Semiconductor Cybersecurity
    SAN JOSE, CA – December 11, 2025 – In a pivotal move poised to redefine the landscape of semiconductor design and cybersecurity, Arteris, Inc. (NASDAQ: APLS), a leading provider of system IP for... 
    Via TokenRing AI
    Topics Artificial Intelligence Economy Intellectual Property

    Performance

    YTD
    N/A
    N/A
    1 Month
    +25.8%
    +25.8%
    3 Month
    +12.5%
    +12.5%
    6 Month
    +42.4%
    +42.4%
    1 Year
    -21.6%
    -21.6%

    More News

    Read More
    News headline image
    APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Emerges as a Prime GARP Investment ↗
    Via Chartmill
    News headline image
    The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For October 30, 2025 ↗
    Via Benzinga
    News headline image
    Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Presents an Affordable Growth Opportunity ↗
    Via Chartmill
    News headline image
    This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power ↗
    Via Benzinga
    News headline image
    Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
    Via Benzinga
    News headline image
    Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    These stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    The market is filled with gapping stocks in Thursday's session. ↗
    Via Chartmill
    News headline image
    Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reports Strong Q3 2025 Earnings Beat ↗
    Via Chartmill
    News headline image
    Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Insights Ahead: Apellis Pharmaceuticals's Quarterly Earnings ↗
    Via Benzinga
    News headline image
    New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 11 Analysts ↗
    Via Benzinga
    News headline image
    12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know ↗
    Via Benzinga
    News headline image
    Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
    Via Benzinga
    Topics Stocks
    News headline image
    Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Apellis Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Apellis Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Apellis Pharmaceuticals, Inc. - Common Stock trade on?
    Apellis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock is APLS on the Nasdaq Stock Market
    What is the current price of Apellis Pharmaceuticals, Inc. - Common Stock?
    The current price of Apellis Pharmaceuticals, Inc. - Common Stock is 26.00
    When was Apellis Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Apellis Pharmaceuticals, Inc. - Common Stock was at 01/02/26 11:58 AM ET
    What is the market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock is 3.03B
    How many shares of Apellis Pharmaceuticals, Inc. - Common Stock are outstanding?
    Apellis Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.